Which has preferable earnings & valuation, BBIO or TLX?

Telix Pharmaceuticals has higher revenue and earnings than BridgeBio Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BridgeBio Pharma $713.07M 22.47 -$724.93M -$3.57 N/A Telix Pharmaceuticals $803.79M 4.79 -$7.12M N/A N/A

Is BBIO or TLX more profitable?

Telix Pharmaceuticals has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -97.03%. Company Net Margins Return on Equity Return on Assets BridgeBio Pharma -97.03% N/A -61.19% Telix Pharmaceuticals N/A N/A N/A

Does the media refer more to BBIO or TLX?

In the previous week, Telix Pharmaceuticals had 5 more articles in the media than BridgeBio Pharma. MarketBeat recorded 13 mentions for Telix Pharmaceuticals and 8 mentions for BridgeBio Pharma. Telix Pharmaceuticals' average media sentiment score of 0.48 beat BridgeBio Pharma's score of 0.41 indicating that Telix Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Telix Pharmaceuticals 3 Very Positive mention(s) 5 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, TLX or ASND?

Telix Pharmaceuticals has higher earnings, but lower revenue than Ascendis Pharma A/S. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 4.79 -$7.12M N/A N/A Ascendis Pharma A/S $814.57M 19.56 -$258M $12.89 19.82

Does the media prefer TLX or ASND?

In the previous week, Telix Pharmaceuticals had 1 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 13 mentions for Telix Pharmaceuticals and 12 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.71 beat Telix Pharmaceuticals' score of 0.48 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 3 Very Positive mention(s) 5 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Ascendis Pharma A/S 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, TLX or BMRN?

BioMarin Pharmaceutical has higher revenue and earnings than Telix Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 4.79 -$7.12M N/A N/A BioMarin Pharmaceutical $3.41B 3.79 $348.90M $0.37 180.16

Does the media favor TLX or BMRN?

In the previous week, BioMarin Pharmaceutical had 21 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 34 mentions for BioMarin Pharmaceutical and 13 mentions for Telix Pharmaceuticals. BioMarin Pharmaceutical's average media sentiment score of 0.74 beat Telix Pharmaceuticals' score of 0.48 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 3 Very Positive mention(s) 5 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral BioMarin Pharmaceutical 13 Very Positive mention(s) 5 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, TLX or EXEL?

Exelixis has higher revenue and earnings than Telix Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 4.79 -$7.12M N/A N/A Exelixis $2.44B 5.53 $782.57M $3.18 17.09

Does the media favor TLX or EXEL?

In the previous week, Telix Pharmaceuticals and Telix Pharmaceuticals both had 13 articles in the media. Exelixis' average media sentiment score of 1.06 beat Telix Pharmaceuticals' score of 0.48 indicating that Exelixis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 3 Very Positive mention(s) 5 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Exelixis 8 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, TLX or MDGL?

Telix Pharmaceuticals has higher earnings, but lower revenue than Madrigal Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 4.79 -$7.12M N/A N/A Madrigal Pharmaceuticals $958.40M 12.55 -$288.28M -$12.89 N/A

Does the media favor TLX or MDGL?

In the previous week, Telix Pharmaceuticals had 6 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 13 mentions for Telix Pharmaceuticals and 7 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 0.78 beat Telix Pharmaceuticals' score of 0.48 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 3 Very Positive mention(s) 5 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Madrigal Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Telix Pharmaceuticals (TLX) Competitors

$11.34 -1.08 (-8.70%)

As of 02:46 PM Eastern

Compare

TLX vs. BBIO, ASND, BMRN, EXEL, and MDGL

Should you buy Telix Pharmaceuticals stock or one of its competitors? Telix Pharmaceuticals's main competitors and comparable companies include BridgeBio Pharma (BBIO), Ascendis Pharma A/S (ASND), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL), and Madrigal Pharmaceuticals (MDGL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Telix Pharmaceuticals compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Telix Pharmaceuticals (NASDAQ:TLX) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and media sentiment.

99.8% of BridgeBio Pharma shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Telix Pharmaceuticals has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -97.03%.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-97.03%	N/A	-61.19%
Telix Pharmaceuticals	N/A	N/A	N/A

BridgeBio Pharma currently has a consensus price target of $100.79, suggesting a potential upside of 22.94%. Telix Pharmaceuticals has a consensus price target of $20.40, suggesting a potential upside of 80.21%. Given Telix Pharmaceuticals' higher possible upside, analysts plainly believe Telix Pharmaceuticals is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Telix Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63

BridgeBio Pharma has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.24, indicating that its stock price is 124% less volatile than the broader market.

In the previous week, Telix Pharmaceuticals had 5 more articles in the media than BridgeBio Pharma. MarketBeat recorded 13 mentions for Telix Pharmaceuticals and 8 mentions for BridgeBio Pharma. Telix Pharmaceuticals' average media sentiment score of 0.48 beat BridgeBio Pharma's score of 0.41 indicating that Telix Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Telix Pharmaceuticals	3 Very Positive mention(s)	5 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Telix Pharmaceuticals has higher revenue and earnings than BridgeBio Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$713.07M	22.47	-$724.93M	-$3.57	N/A
Telix Pharmaceuticals	$803.79M	4.79	-$7.12M	N/A	N/A

Summary

Telix Pharmaceuticals beats BridgeBio Pharma on 8 of the 14 factors compared between the two stocks.

How does Telix Pharmaceuticals compare to Ascendis Pharma A/S?

Telix Pharmaceuticals (NASDAQ:TLX) and Ascendis Pharma A/S (NASDAQ:ASND) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

Telix Pharmaceuticals has higher earnings, but lower revenue than Ascendis Pharma A/S.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	4.79	-$7.12M	N/A	N/A
Ascendis Pharma A/S	$814.57M	19.56	-$258M	$12.89	19.82

In the previous week, Telix Pharmaceuticals had 1 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 13 mentions for Telix Pharmaceuticals and 12 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.71 beat Telix Pharmaceuticals' score of 0.48 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	3 Very Positive mention(s)	5 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ascendis Pharma A/S	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Telix Pharmaceuticals presently has a consensus target price of $20.40, indicating a potential upside of 80.21%. Ascendis Pharma A/S has a consensus target price of $300.33, indicating a potential upside of 17.56%. Given Telix Pharmaceuticals' higher possible upside, analysts clearly believe Telix Pharmaceuticals is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.05

Telix Pharmaceuticals has a beta of -0.24, meaning that its share price is 124% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market.

Ascendis Pharma A/S has a net margin of 70.99% compared to Telix Pharmaceuticals' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 32.54% beat Telix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Ascendis Pharma A/S	70.99%	32.54%	7.71%

Summary

Ascendis Pharma A/S beats Telix Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

How does Telix Pharmaceuticals compare to BioMarin Pharmaceutical?

Telix Pharmaceuticals (NASDAQ:TLX) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations.

BioMarin Pharmaceutical has a net margin of 2.14% compared to Telix Pharmaceuticals' net margin of 0.00%. BioMarin Pharmaceutical's return on equity of 5.32% beat Telix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
BioMarin Pharmaceutical	2.14%	5.32%	3.69%

Telix Pharmaceuticals has a beta of -0.24, indicating that its stock price is 124% less volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market.

In the previous week, BioMarin Pharmaceutical had 21 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 34 mentions for BioMarin Pharmaceutical and 13 mentions for Telix Pharmaceuticals. BioMarin Pharmaceutical's average media sentiment score of 0.74 beat Telix Pharmaceuticals' score of 0.48 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	3 Very Positive mention(s)	5 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioMarin Pharmaceutical	13 Very Positive mention(s)	5 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

BioMarin Pharmaceutical has higher revenue and earnings than Telix Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	4.79	-$7.12M	N/A	N/A
BioMarin Pharmaceutical	$3.41B	3.79	$348.90M	$0.37	180.16

Telix Pharmaceuticals presently has a consensus target price of $20.40, suggesting a potential upside of 80.21%. BioMarin Pharmaceutical has a consensus target price of $88.83, suggesting a potential upside of 33.25%. Given Telix Pharmaceuticals' higher possible upside, equities analysts clearly believe Telix Pharmaceuticals is more favorable than BioMarin Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.75

98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 0.7% of BioMarin Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

BioMarin Pharmaceutical beats Telix Pharmaceuticals on 13 of the 15 factors compared between the two stocks.

How does Telix Pharmaceuticals compare to Exelixis?

Telix Pharmaceuticals (NASDAQ:TLX) and Exelixis (NASDAQ:EXEL) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

Telix Pharmaceuticals has a beta of -0.24, suggesting that its stock price is 124% less volatile than the broader market. Comparatively, Exelixis has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market.

85.3% of Exelixis shares are owned by institutional investors. 2.6% of Exelixis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Exelixis has a net margin of 35.33% compared to Telix Pharmaceuticals' net margin of 0.00%. Exelixis' return on equity of 42.17% beat Telix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Exelixis	35.33%	42.17%	31.76%

In the previous week, Telix Pharmaceuticals and Telix Pharmaceuticals both had 13 articles in the media. Exelixis' average media sentiment score of 1.06 beat Telix Pharmaceuticals' score of 0.48 indicating that Exelixis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	3 Very Positive mention(s)	5 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Exelixis	8 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Telix Pharmaceuticals currently has a consensus price target of $20.40, suggesting a potential upside of 80.21%. Exelixis has a consensus price target of $50.07, suggesting a potential downside of 7.88%. Given Telix Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Telix Pharmaceuticals is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63
Exelixis	2 Sell rating(s)	11 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.30

Exelixis has higher revenue and earnings than Telix Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	4.79	-$7.12M	N/A	N/A
Exelixis	$2.44B	5.53	$782.57M	$3.18	17.09

Summary

Exelixis beats Telix Pharmaceuticals on 11 of the 13 factors compared between the two stocks.

How does Telix Pharmaceuticals compare to Madrigal Pharmaceuticals?

Telix Pharmaceuticals (NASDAQ:TLX) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

In the previous week, Telix Pharmaceuticals had 6 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 13 mentions for Telix Pharmaceuticals and 7 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 0.78 beat Telix Pharmaceuticals' score of 0.48 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	3 Very Positive mention(s)	5 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Madrigal Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Telix Pharmaceuticals presently has a consensus price target of $20.40, indicating a potential upside of 80.21%. Madrigal Pharmaceuticals has a consensus price target of $689.93, indicating a potential upside of 32.52%. Given Telix Pharmaceuticals' higher possible upside, analysts clearly believe Telix Pharmaceuticals is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

Telix Pharmaceuticals has higher earnings, but lower revenue than Madrigal Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	4.79	-$7.12M	N/A	N/A
Madrigal Pharmaceuticals	$958.40M	12.55	-$288.28M	-$12.89	N/A

Telix Pharmaceuticals has a beta of -0.24, meaning that its share price is 124% less volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -1.01, meaning that its share price is 201% less volatile than the broader market.

98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Telix Pharmaceuticals has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -25.32%. Telix Pharmaceuticals' return on equity of 0.00% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%

Summary

Telix Pharmaceuticals beats Madrigal Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Get Telix Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TLX vs. The Competition

Export

Metric	Telix Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.85B	$4.03B	$7.31B	$12.81B
Dividend Yield	N/A	3.64%	2.54%	10.69%
P/E Ratio	N/A	11.67	271.76	24.15
Price / Sales	4.79	1,277.63	597.83	79.02
Price / Cash	287.45	103.92	78.13	53.57
Price / Book	9.20	18.02	13.43	6.37
Net Income	-$7.12M	-$12.54M	$3.46B	$347.61M
7 Day Performance	-4.23%	3.10%	1.99%	-0.06%
1 Month Performance	3.66%	6.34%	4.87%	1.98%
1 Year Performance	-6.37%	59.62%	27.51%	20.45%

Telix Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TLX Telix Pharmaceuticals	4.5973 of 5 stars	$11.34 -8.7%	$20.40 +79.9%	+13.2%	$3.85B	$803.79M	N/A	1,184	Trending News Analyst Forecast Gap Down
BBIO BridgeBio Pharma	3.149 of 5 stars	$82.53 +3.3%	$100.79 +22.1%	+69.7%	$16.04B	$713.07M	N/A	400	Insider Trade
ASND Ascendis Pharma A/S	4.5326 of 5 stars	$249.66 +0.9%	$299.24 +19.9%	+32.2%	$15.57B	$814.57M	19.37	1,189	Earnings Report Analyst Forecast Insider Trade
BMRN BioMarin Pharmaceutical	4.8172 of 5 stars	$68.04 +2.1%	$88.41 +29.9%	+16.8%	$13.17B	$3.41B	183.93	3,221	Analyst Forecast
EXEL Exelixis	3.3626 of 5 stars	$53.02 +1.3%	$49.79 -6.1%	+41.8%	$13.13B	$2.44B	16.67	1,077	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TLX) was last updated on 8/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Telix Pharmaceuticals (TLX) Competitors

TLX vs. BBIO, ASND, BMRN, EXEL, and MDGL

How does Telix Pharmaceuticals compare to BridgeBio Pharma?

Summary

How does Telix Pharmaceuticals compare to Ascendis Pharma A/S?

Summary

How does Telix Pharmaceuticals compare to BioMarin Pharmaceutical?

Summary

How does Telix Pharmaceuticals compare to Exelixis?

Summary

How does Telix Pharmaceuticals compare to Madrigal Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLX vs. The Competition

Telix Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Telix Pharmaceuticals (TLX) Competitors

TLX vs. BBIO, ASND, BMRN, EXEL, and MDGL

How does Telix Pharmaceuticals compare to BridgeBio Pharma?

Do institutionals & insiders hold more shares of BBIO or TLX?

Is BBIO or TLX more profitable?

Do analysts recommend BBIO or TLX?

Which has more volatility & risk, BBIO or TLX?

Does the media refer more to BBIO or TLX?

Which has preferable earnings & valuation, BBIO or TLX?

Summary

How does Telix Pharmaceuticals compare to Ascendis Pharma A/S?

Which has better earnings and valuation, TLX or ASND?

Does the media prefer TLX or ASND?

Do analysts recommend TLX or ASND?

Which has more risk and volatility, TLX or ASND?

Is TLX or ASND more profitable?

Summary

How does Telix Pharmaceuticals compare to BioMarin Pharmaceutical?

Is TLX or BMRN more profitable?

Which has more volatility and risk, TLX or BMRN?

Does the media favor TLX or BMRN?

Which has preferable valuation & earnings, TLX or BMRN?

Do analysts recommend TLX or BMRN?

Do institutionals and insiders hold more shares of TLX or BMRN?

Summary

How does Telix Pharmaceuticals compare to Exelixis?

Which has more risk and volatility, TLX or EXEL?

Do institutionals and insiders hold more shares of TLX or EXEL?

Is TLX or EXEL more profitable?

Does the media favor TLX or EXEL?

Do analysts rate TLX or EXEL?

Which has higher earnings and valuation, TLX or EXEL?

Summary

How does Telix Pharmaceuticals compare to Madrigal Pharmaceuticals?

Does the media favor TLX or MDGL?

Do analysts rate TLX or MDGL?

Which has preferable earnings and valuation, TLX or MDGL?

Which has more risk & volatility, TLX or MDGL?

Do insiders & institutionals have more ownership in TLX or MDGL?

Is TLX or MDGL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLX vs. The Competition

Telix Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools